city New Delhi India covid-19 death prevention patient city New Delhi India

Biocon Biologics starts clinical trial of drug for severe covid-19 complications

Reading now: 670
www.livemint.com

NEW DELHI: Biocon Biologics India has started clinical trials of its novel biologic itolizumab for treating cytokine storms, which is one of the leading causes of death among critical covid-19 patients.

The novel biologic was launched by the company in 2013 for treating plaque psoriasis. The company is now repurposing the drug for prevention and treatment of covid-19 complications after seven years of post-marketing safety data.

The subsidiary of Biocon Ltd has received approval from the Drug Controller General of India (DCGI) for clinical trials of itolizumab in patients with covid-19 complications, Sandeep Athalye, senior vice president and chief medical officer of Biocon Biologics, told Mint in a statement. “We believe that the unique

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA